Liver cancer vaccine works. Promising in reducing cancer lesions

According to a study published in the scientific journal Nature Medicine, in a third of patients with advanced liver cancer who received a personalized vaccine, the malignant tumor shrank. We are talking about Hepatocellular carcinoma (HCC), the most common form of primary liver cancer It is the leading cause of cancer deaths worldwide.

Every year, more than 800,000 people are diagnosed with this cancer around the world. People, it also causes more than 700 thousand deaths annually Even despite advances in treating advanced forms of this cancer, the 5-year survival rate remains less than 10%. Worse still, it is also expected that between 2020 and 2040, the number of new liver cancer cases per year will increase by 55%. In 2040, 1.3 million people may die from liver cancer.

The first and last patients were enrolled in the study on June 16, 2020 and June 14, 2023, respectively, and a total of 36 subjects received the allocated vaccine. They were designated because researchers used samples of a patient's tumor to build vaccines based on new mutations found in a particular patient's tumor — the results suggest that This type of solution can strengthen the patient's immune system and thus improve the ability to recognize and fight cancer.